Wilson M, Pedersen SG, Langeland N, Cox RJ, Aukrust P, Dahl TB, Sandvig A, Wilhelmsen M(2026) Tailored Individual Follow-Ups Versus a One-Day Group Course in Patients With Long COVID (Post- COVID-19 Condition): Protocol for a Randomized Controlled Trial JMIR Res Protoc, 15, e74113 DOI 10.2196/74113, PubMed 41490577
Publications 2025
Massonnaud CR, Peiffer-Smadja N, Poignard P, Jamard S, Goehringer F, Danion F, Reignier J, de Castro N, Garot D, Lapique EL, Lacombe K, Tolsma V, Faure E, Malvy D, Staub T, Courjon J, Cazenave-Roblot F, Dyrhol Riise AM, Leturnier P, Martin-Blondel G, Roger C, Akinosoglou K, Vincent Le Moing, Piroth L, Sellier Pet al.(2025) Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trial Clin Microbiol Infect(in press) DOI 10.1016/j.cmi.2025.12.014, PubMed 41429349
Tunheim G, Baranowska-Hustad M, Lund-Johansen F, Fossum E, Bhandari S, Kukule L, Møller TKR, Vikse EL, Bekkevold T, Oftung F, Robertson AH, Næss LM(2025) SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway APMIS, 133(12), e70102 DOI 10.1111/apm.70102, PubMed 41376258
